NASDAQ$ANIK

Anika Therapeutics Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Anika reported a 7% year-over-year revenue growth in the first quarter, driven by favorable order timing in OA Pain Management.

Anika Therapeutics reported a strong start to 2022 with a 7% year-over-year revenue growth. The company is experiencing healthy demand for OA Pain Management products and growing demand for the Joint Preservation and Restoration portfolio. They are ramping up medical education activities and planning new product introductions.

  • First quarter revenue growth of 7% year-over-year.
  • Growth driven by favorable order timing in OA Pain Management.
  • Continued healthy demand for OA Pain Management products.
  • Growing demand for Joint Preservation and Restoration portfolio.

Headline financials

Total Revenue

$36.7M

Previous: $34.3M+7.0%
EPS (adj)

-$0.11

Previous: $0.06-283.3%
Capital Expenditures

-$1.33M

Previous: -$417K-218.0%
Free Cash Flow

-$4.26M

Previous: $2.42M-275.9%
Net Income

-$2.93M

Previous: $2.84M-203.3%
Operating Income

-$3.55M

Previous: $1.26M-382.5%
Gross Profit

$21.8M

Previous: $21M+4.0%
Cash & Equivalents

$90.3M

Previous: $94.6M-4.5%
Total Assets

$342M

Previous: $362M-5.5%
Stock-Based Comp

$2.55M

Previous: $2.26M+12.7%

Revenue & EPS history

Anika · Revenue · Quarterly

$36.7M

Q1 2022+7%vs Q1 2021
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Forward guidance

The Company expects its overall revenue for fiscal year 2022 to be toward the upper end of its guidance range of low to mid-single digit percent growth compared with 2021.

Headwinds

  • Volatility and uncertainty in the global macroeconomic environment.
  • Staffing shortages.
  • Supply chain disruption.
  • Inflation.
  • Direct and indirect impacts of the COVID pandemic.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+0.1%

Avg return

Earnings day

-3.0%

Avg return

5 days after

-2.8%

Avg return

30 days after

51%

33 / 65 earnings

Positive

+32.1%

Q3 2019

Best reaction

-33.0%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-18.8%-4.7%-4.8%
Q4 2025+16.8%+31.6%+30.5%
Q3 2025+0.8%-0.5%+2.1%
Q1 2025-20.7%-23.2%-23.0%
Q4 2024-11.1%-7.3%-20.3%
Q3 2024-33.0%-34.0%-28.2%
Q2 2024-1.0%-3.6%-5.4%
Q1 2024-10.9%-9.9%-9.1%
Q4 2023-4.8%-2.0%-3.1%
Q3 2023+7.4%+6.7%+15.2%
Q2 2023-4.9%-12.7%-18.0%
Q1 2023-2.8%-3.2%+3.2%
Q4 2022-18.0%-17.4%-10.4%
Q3 2022+0.3%+5.3%+6.3%
Q2 2022-4.9%-2.7%-6.0%
Q1 2022-4.9%-3.8%+1.1%
Q4 2021-15.9%-18.0%-20.1%
Q3 2021+3.1%-8.2%-12.8%
Q2 2021+1.0%+0.8%+1.3%
Q1 2021+1.3%+2.8%+10.9%
Q4 2020-10.5%-12.1%+3.9%
Q3 2020-3.3%+0.2%+7.6%
Q2 2020+0.3%-8.7%+2.9%
Q1 2020-9.9%-12.2%+9.1%
Q4 2019+0.4%+0.1%-39.5%
Q3 2019+32.1%+21.5%+3.7%
Q2 2019+29.1%+31.0%+37.2%
Q1 2019+19.6%+21.5%+15.9%
Q4 2018-15.3%-18.8%-26.5%
Q3 2018-11.0%-13.6%-13.9%
Q2 2018+18.6%+15.0%+20.8%
Q1 2018-22.9%-15.7%-8.6%
Q4 2017-4.0%-11.3%-17.4%
Q3 2017-8.0%-9.2%-8.0%
Q2 2017+7.1%+6.0%+9.3%
Q1 2017-5.5%-1.8%+0.4%
Q4 2016-5.0%-5.1%-16.4%
Q3 2016+2.0%+2.7%+8.0%
Q2 2016-5.0%-2.3%-6.7%
Q1 2016+0.5%
Q4 2015+11.2%
Q3 2015+12.5%
Q2 2015+3.2%
Q1 2015-7.5%
Q4 2014-10.7%
Q3 2014+1.0%
Q2 2014+4.1%
Q1 2014+7.7%
Q4 2013+26.9%
Q3 2013+6.5%
Q2 2013+21.9%
Q1 2013-1.8%
Q4 2012+16.6%
Q3 2012-7.7%
Q2 2012+24.4%
Q1 2011+0.6%
Q1 2012+2.8%
Q4 2009+1.5%
Q4 2011+1.5%
Q3 2011+7.0%
Q3 2010+7.0%
Q2 2010-3.4%
Q4 2010-3.4%
Q2 2011-3.4%
Q1 2010-1.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro